Both& Discovery, a Public Benefit Corporation, is dedicated to the exploration of serotonin agonists to treat diabetic peripheral neuropathy and related diseases. Our explorations of synthetics are based in the work of Sasha Shulgin and the Alexander Shulgin Research Institute. Both&'s founding team includes well known figures from the psychedelic business world, James Keim and attorney Graham Pechenik. James and Graham are diabetics whose personal experiences with neuropathy provided the initial inspiration for this company.

 

The name Both& was inspired by the expression, "not either or, but both and." We sidestep dualistic constructs which insist on choices between open source and patented approaches, natural vs synthetic, and public good vs profits. We believe that it is possible to simultaneously create natural, open-source formulations and patented, synthetic therapeutics (requiring FDA approval) without there being competition between the two; both should be made available to the world.

​

The availability of open source, natural therapeutics is especially important where there is a local ability to create natural medicines but a financial inability to import Western pharmaceuticals.

​

Both& Discovery does not believe in patenting nature, and our approach to novel inventions includes patent pledges within the body of patent applications. These patent pledges encourage, within generous limits, royalty-free use of our technologies by individuals, small businesses, and businesses within developing countries and especially by traditionally marginalized groups.

​

​